Current Research Studies
Research Home Page
Current Research Studies
Frequently Asked Questions
Research Team Members
Child and Adolescent Psychiatry Research
Our research opportunities provide a wide range of treatment options for children and adolescents. All research participants are formally diagnosed, carefully monitored and closely followed for safety and response throughout their involvement. The study staff members always are available for questions or more information at (414) 266-3126.
Current enrolling studies include:
For children and adolescents with Bipolar I Disorder:
preschool
Children, ages 3 to 7 years, with Bipolar I Disorder or Bipolar II Disorder may be eligible to participate in this 6-week study on an outpatient basis. Patients will be randomly assigned to either valproate, risperidone or placebo at a 2:2:1 ratio. This study is designed to provide a systematic evaluation of the safety and efficacy of valproate and risperidone in pediatric patients with Bipolar Disorder.
neuropsychology
Children and adolescents, ages 10 to 17 years, with Bipolar I Disorder may be eligible to participate in this 2-visit study. The first visit lasts approximately one hour. Participants will be asked a series of questions to confirm present diagnosis and lifetime history of mental health. The second visit requires approximately two-and-one-half hours of testing time and will be completed in one day if possible. The tests given during the second visit will assess intelligence, academic achievement, learning and memory, problem solving, coordination and attention.
For adolescents with psychosis, including Schizophrenia:
ziprasidone (Geodon)
Adolescents, ages 13 to 17 years, with Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder or Psychotic Disorder NOS, and without a history of heart problems, may be eligible to participate in this 6-week double-blind study. Patients randomly will be assigned to ziprasidone or placebo at a 2:1 ratio. This study is designed to provide a systematic evaluation of the safety and efficacy of ziprasidone in pediatric patients with Schizophrenia. A 6-month open-label extension study is offered.
|
